Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 7.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,486 shares of the company’s stock after acquiring an additional 684 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Moderna were worth $1,043,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Allworth Financial LP boosted its holdings in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association grew its position in shares of Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after buying an additional 102 shares during the last quarter. Sound Income Strategies LLC grew its position in shares of Moderna by 17.8% during the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after buying an additional 115 shares during the last quarter. IFP Advisors Inc raised its stake in Moderna by 18.8% during the third quarter. IFP Advisors Inc now owns 834 shares of the company’s stock worth $86,000 after acquiring an additional 132 shares during the period. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its holdings in Moderna by 6.5% in the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock worth $245,000 after acquiring an additional 151 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of Moderna stock traded up $1.79 on Friday, hitting $107.97. The company had a trading volume of 2,245,667 shares, compared to its average volume of 4,077,747. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The company has a market cap of $41.34 billion, a PE ratio of -8.70 and a beta of 1.62. The business has a 50-day simple moving average of $102.15 and a 200-day simple moving average of $93.73.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. During the same period last year, the company posted $3.61 EPS. The firm’s quarterly revenue was down 44.9% on a year-over-year basis. Research analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now directly owns 8,557 shares in the company, valued at $809,235.49. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the transaction, the insider now owns 8,557 shares in the company, valued at $809,235.49. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders sold 109,954 shares of company stock valued at $11,533,976 over the last 90 days. 15.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on MRNA. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. HSBC restated a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Royal Bank of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Moderna in a report on Thursday, March 28th. Finally, Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.